SGLT2i tied to lower mortality and better outcomes than DPP4i, finds Study

Italy: Initiation of SGLT2 inhibitors under routine care versus initiation of DPP4 inhibitors leads to better cardiorenal outcomes and lower mortality in patients with type 2 diabetes, a recent study has pointed. The study is published in the journal Diabetes Research and Clinical Practice.

Both dipeptidyl peptidase-4 (DPP4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors are used for the treatment of type 2 diabetes that is inadequately controlled with insulin therapy. Yet, no comparison has been made between these two inhibitors. To fill this knowledge gap, Gian Paolo Fadini, Veneto Institute of Molecular Medicine, Padua, Italy, and colleagues aimed to compared cardiovascular outcomes of patients with type 2 diabetes (T2D) receiving SGLT2i or dipeptidyl DPP4i under routine care.

To determine the above, the researchers identified patients with T2D who initiated SGLT2i or DPP4i from an administrative claims database of >5,2M citizens from 2014 to 2018. Patients were matched by propensity scores. The primary outcome was the 3-point major adverse cardiovascular events (3P-MACE).

After matching, 3216 patients were included in each group (mean age 63 years, diabetes duration of 8.7 years, and 20% had cardiovascular disease). After a median follow-up of 18 months, the researchers found the following: 

Based on the above findings the authors concluded that, "Patients with T2D who initiated SGLT2i under routine care had better cardio-renal outcomes and lower all-cause mortality than similar patients who initiated DPP4i."

Reference:

The study titled, "Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies," is published in the journal Diabetes Research and Clinical Practice. 

DOI: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(21)00383-1/fulltext